Related Experiment Video
Updated: Aug 9, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Integrated technology platform protein kinases for drug development in oncology
Christoph Sachsenmaier1, Christoph Schächtele
1ProQinase GmbH, Freiburg, Germany. c.sachsenmaier@proqinase.com
Abstract:
Protein kinases are among the most promising targets for drug discovery and development, mostly in oncology but also in other fields such as inflammation, Alzheimer's, and infectious diseases. The Integrated Technology Platform Protein Kinases was designed as a comprehensive tool for drug discovery in thefield of oncology. It combines modules for the identification and validation of novel target protein kinases, a unique panel of active recombinant protein kinases, high-throughput screening, selectivity profiling, cellular testing, and in vivo tumor models. Here we give an overview of the Integrated Technology Platform Protein Kinases as well as data that validate each module.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

